The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The companies aim to expand treatment options for millions living with metabolic disorders
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
